Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMM1JL9)

Drug Name
Amcinonide Drug Info
Synonyms
Amcinonida; Amcinonido; Amcinonidum; Cyclocort; Cyclort; Triamcinolonacetatcyclopentanonid; Visderm; CL 34699; Amcinonido [INN-Spanish]; Amcinonidum [INN-Latin]; CL 34,699; CL-34699; Cyclocort (TN); Amcinonide (JAN/USP/INN); Amcinonide [USAN:INN:BAN:JAN]; Triamcinolone 16,17-cyclopentylidenedioxy-21-acetate; 1,4-Pregnadiene-2,20-dione-16,17-cyclopentylidenedioxy-9-fluoro-11,21-dihydroxy-21-acetate; 16alpha,17alpha-(cyclopentane-1,1-diyldioxy)-9-fluoro-11beta-hydroxy-3,20-dioxopregna-1,4-dien-21-yl acetate; 19alpha-Fluor-11beta,21-dihydroxy-16alpha,17alpha-(tetramethylen)methylendioxy-1,4-pregnadien-3,20-dion 21-acetat; 9-Fluoro-11beta,16alpha,17,21-tetrahydroxypregna-1,4-diene-3,20-dione cyclic 16,17-acetal with cyclopentanone, 21-acetate
Therapeutic ClassAntiinflammatory Agents
Cross-matching ID
PubChem CID
443958
ChEBI ID
CHEMBL31199
CAS Number
CAS 51022-69-6
TTD Drug ID
D06XHC
INTEDE Drug ID
DR0082
ACDINA Drug ID
D00830

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
DNA replication 2.02 9.74e-3 34/36 (94.44%) POLE2;PRIM1;MCM6;...
Fatty acid degradation 1.99 4.87e-3 40/43 (93.02%) ACSL1;ADH5;ADH1B;...
Peroxisome 1.97 1.30e-2 72/82 (87.8%) ACSL1;FAR2;EPHX2;...
Proximal tubule bicarbonate reclamation 1.92 1.95e-2 21/23 (91.3%) CA2;ATP1B3;CA4;...
Drug metabolism 1.89 1.95e-2 78/151 (51.66%) MAOA;NAT1;ADH5;...
Adipocytokine signaling pathway 1.86 2.92e-2 64/69 (92.75%) NFKBIA;ACSL1;CD36;...
PPAR signaling pathway 1.85 2.50e-2 66/74 (89.19%) MMP1;LPL;ACSL1;...
Pyruvate metabolism 1.84 2.19e-2 41/47 (87.23%) ADH5;ADH1B;DLAT;...
Fatty acid biosynthesis 1.81 2.49e-2 16/18 (88.89%) ACSL1;ACSL3;ACACB;...
Oxidative phosphorylation 1.81 2.24e-2 93/133 (69.92%) PPA2;NDUFA9;NDUFA8;...
Folate biosynthesis 1.76 3.36e-2 23/26 (88.46%) QDPR;GCH1;PTS;...
Propanoate metabolism 1.75 3.16e-2 30/34 (88.24%) SUCLA2;ECHDC1;ACAT2;...
Tyrosine metabolism 1.75 2.92e-2 30/36 (83.33%) MAOA;ADH5;ADH1B;...
Fatty acid elongation 1.74 2.85e-2 19/27 (70.37%) HACD2;PPT1;ACAA2;...
Cardiac muscle contraction 1.69 3.83e-2 64/87 (73.56%) ATP1B3;ATP1A1;TNNC1;...
Citrate cycle (TCA cycle) 1.69 3.59e-2 30/30 (100%) DLAT;IDH3A;SUCLA2;...
Protein digestion and absorption 1.68 3.49e-2 78/103 (75.73%) SLC1A1;COL3A1;SLC38A2;...
Arginine biosynthesis 1.67 3.41e-2 17/22 (77.27%) ASS1;GLUL;GOT1;...
One carbon pool by folate 1.67 3.38e-2 15/20 (75%) SHMT1;MTHFD1;DHFR;...
Glycine, serine and threonine metabolism 1.65 4.19e-2 31/40 (77.5%) MAOA;AOC3;PGAM1;...
Mismatch repair 1.64 4.68e-2 22/23 (95.65%) POLD3;PCNA;RPA3;...
Melanogenesis -1.78 3.09e-2 74/101 (73.27%) PLCB1;CAMK2A;DVL1;...
Wnt signaling pathway -1.84 2.06e-2 124/166 (74.7%) MMP7;JUN;NFATC4;...
Breast cancer -1.86 2.23e-2 119/147 (80.95%) JAG1;GADD45A;WNT7A;...
Notch signaling pathway -1.91 1.44e-2 49/59 (83.05%) KAT2B;CTBP2;KAT2A;...
Other glycan degradation -1.98 5.15e-3 13/18 (72.22%) HEXB;MAN2C1;GLB1;...
Hepatocellular carcinoma -1.99 0.00e+0 135/168 (80.36%) PRKCB;GSTA3;FZD5;...
Signaling pathways regulating pluripotency of stem cell... -2.06 0.00e+0 110/143 (76.92%) INHBB;WNT7A;PIK3R3;...
Basal cell carcinoma -2.19 0.00e+0 41/63 (65.08%) DVL1;FZD5;GADD45A;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 10uM 6H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 2.22uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 2.22uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
ASC CVCL_U602 Homo sapiens 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 2.22uM 24H
Liver
Hepatoblastoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Hep G2 CVCL_0027 Homo sapiens 10uM 6H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HCC515 CVCL_5134 Homo sapiens 10uM 6H, 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 2.22uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 2.22uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H